Why GLP-1 medicines are not standard treatment for type 1 diabetes
Type 1 diabetes is a different disease from type 2. In type 1, the immune system destroys the beta cells that make insulin, so the body makes little or no insulin. GLP-1 medicines like Ozempic and Mounjaro work partly by telling the body to release insulin when blood sugar rises. When the beta cells are gone, that benefit is limited. These medicines are not approved for type 1 diabetes and are not a replacement for insulin. Some small studies looked at GLP-1 as an add-on to insulin in type 1, with modest sugar, weight and insulin-dose benefits, but they also saw more low sugars and ketosis risk. Insulin remains the foundation of type 1 care. This is a plain explainer, not medical advice; your diabetologist decides.
Unlock the complete article
Register with just your mobile number and OTP. No password and no payment.